Edward Kai-Hua CHOW

Principal Investigator, Cancer Science Institute of Singapore, NUS
NUS Associate Professor, Department of Pharmacology, Yong Loo Lin School of Medicine, NUS


The Chow laboratory seeks to improve cancer therapy, especially in the context of combination therapy, through multidisciplinary methods that include engineering-based approach, such as AI, nanotechnology and automated laboratory systems. We are particularly interested in how to quickly and accurately identify effective cancer therapeutic options for individual cancer patients as well as specific sub-groups of cancer patients in both blood cancers and solid tumors. Additionally, we seek to understand how the molecular mechanisms behind why specific patients or groups of patients respond to specific therapies and how this can be applied towards broader cancer populations.


The Chow laboratory is interested in a developing a comprehensive translational approach to understanding and treating cancer. Through the incorporation of AI, nanotechnology, automated combinatorial drug screening and biochemistry, improved cancer therapy approaches as well as the molecule mechanisms that underpin their efficacy can be quickly developed. We are particularly interested in using technology to develop truly personalised medical approaches that can identify the best therapeutic options for individual patients. While providing valuable insight into effective therapies for specific patients, this data is also used to identify critical molecular mechanisms of cancer pathogenesis that are worth further interrogation. While we are interested in a wide range of cancers, much of this progress has been made primarily in lymphomas, myeloma and gastrointestinal cancers. Beyond demonstrating that personalised medicine is possible in these cancers, we are focused on understanding the molecular mechanisms by which epigenetics affects these cancers as a number of novel effective epigenetic-based combinations have been identified across a wide range of patient samples. Understanding the mechanisms that underpin the efficacy of epigenetic-based therapy in individual patient samples will allow us to provide greater scientific rationale towards application of epigenetic-based combinations across a broader range of cancer patients as well as improve epigenetic drug development.

Lab Members

Selected Publications

1. Loh KP, Ho D, Chiu GNC, Leong DT, Pastorin G, Chow EK; Clinical Applications of Carbon Nanomaterials in Diagnostics and Therapy.; Adv Mater. 2018 Aug 21:e1802368.

2. Rashid M, Toh TB, Hooi L, Silva A, Zhang Y, Tan PF, The AL, Karnani N, Jha S, Ho CM, Chng WJ, Ho D, Chow EK; Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP); Sci Transl Med. 2018 Aug 8;10(453).

3. Fong ELS, Toh TB, Lin QXX, Liu Z, Hooi L, Rashid MBMA, Benoukraf T, Chow EK, Huynh TH, Yu H.; Datasets describing the growth and molecular features of hepatocellular carcinoma patient-derived xenograft cells grown in a three-dimensional macroporous hydrogel.; Data Brief. 2018 Mar 17;18:594-606.

4. Zhao Y, Shuen TWH, Toh TB, Chan XY, Liu M, Tan SY, Fan Y, Yang H, Lyer SG, Bonney GK, Loh E, Chang KTE, Tan TC, Zhai W, Chan JKY, Chow EK, Chee CE, Lee GH, Dan YY, Chow PK, Toh HC, Lim SG, Chen Q.; Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.; Gut. 2018 Mar 30.

5. Fong ELS, Toh TB, Lin X, Liu Z, Hooi L, Mohd Abdul Rashid MB, Benoukraf T, Chow EK (co-corresponding), Huynh TH, Yu H; Generation of Matched Patient-Derived Xenograft In Vitro-In Vivo Models Using 3D Macroporous Hydrogels for the Study of Liver Cancer; Biomaterials; Jan 2018 doi.org/10.1016/j.biomaterials.2017.12.026

6. Gu M, Wang X, Toh TB, Chow EK. ; Applications of stimuli-responsive nanoscale drug delivery systems in translational research.; Drug Discov Today. 2017 Nov 16.

7. Ho JC, Abdullah LN, Pang QY, Jha S, Chow EK, Yang H, Kato H, Poellinger L, Ueda J, Lee KL; Inhibition of the H3K9 methyltransferase G9A attenuates oncogenicity and activates the hypoxia signaling pathway; PLoS One. 2017 Nov 16;12(11):e0188051.

8. Lee DK, Kee T, Liang Z, Hsiou D, Miya D, Wu B, Osawa E, Chow EK, Sung EC, Kang MK, Ho D.; Clinical validation of a nanodiamond-embedded thermoplastic biomaterial.; Proc Natl Acad Sci U S A. 2017 Oct 23.

9. Wang X, Gu M, Toh TB, Abdullah NLB, Chow EK; Stimuli-Responsive Nanodiamond-Based Biosensor for Enhanced Metastatic Tumor Site Detection.; SLAS Technol. 2017 Oct.

10. Syn NL, Wang L, Chow EK, Lim CT, Goh BC.; Exosomes in Cancer Nanomedicine and Immunotherapy: Prospects and Challenges.; Trends Biotechnol. 2017 Mar 29.